Alina Purschke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alina Purschke has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anja Strangfeld
Programmbereich Epidemiologie und Versorgungsforschung, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Deutschland
2 shared publications Vera Zietemann
Epidemiology and Health Services Research, German Rheumatology Research Center, Berlin, Germany
2 shared publicationsAdrian Richter
Epidemiology and Health Services Research, German Rheumatology Research Center, Berlin, Germany
1 shared publication- Adrian Richter
Department of Prevention Research and Social Medicine, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
1 shared publication - Anne Constanze Regierer
German Rheumatology Research Center (DRFZ Berlin), Epidemiology and Health Services Research, Berlin, Germany
1 shared publication Cornelia Kühne
Rheumatological practice, Haldensleben, Germany
1 shared publication
Latest Publications
- Open Access
Invasive fungal infections in patients with rheumatoid arthritis: an explorative analysis from the German RABBIT register
Objectives: To explore characteristics and treatment of patients with rheumatoid arthritis (RA) with invasive fungal infections (IFIs) and to describe infection details and outcome. Methods: IFIs reported to the German RABBIT (Rheumatoid Arthritis: Observation of Biologic Therapy) register between May 2001 and December 2023 were analysed using a two-stage approach. First, a detailed case description, including a comparison of cases by infection outcome, was conducted using routine register data and hospital discharge letters. Second, a multivariable time-dependent Cox regression model was fitted to analyse associations with IFI development using routine register data only. Results: Among 22 535 patients with RA, 69 IFIs occurred (incidence rate: 0.65/1000 patient-years), with a case fatality of 35% (n=24). Causative pathogens were Pneumocystis jirovecii (35%), Candida spp (33%) and Aspergillus spp (13%). Patients with IFIs were on average 65.4 years old; 54% were female, 80% ever-smokers, 84% glucocorticoid (GC) users and 91% had any infection-risk associated comorbidity at hospitalisation. IFI development was associated with older age (HR 1.36 per 10 years (95% CI 1.05 to 1.76)), male sex (HR 1.92 (95% CI 1.14 to 3.21)), ever-smoking (HR 2.43 (95% CI 1.35 to 4.37)), cardiovascular disease (HR 3.03 (95% CI 1.80 to 5.10)), chronic lung disease (HR 2.09 (95% CI 1.21 to 3.61)), other autoimmune disease (HR 2.11 (95% CI 1.10 to 4.07)), and the use of GCs (HR 1.17 (95% CI 1.11 to 1.22)). Conclusion: In patients with RA, IFIs are rare but life-threatening. They occur particularly in patients who are predisposed to infection due to relevant comorbidities, a history of smoking or both. Except for GC use, the overall impact of targeted RA treatment on the risk of IFI appears to be less relevant than that of multimorbidity.
Open AccessInvasive fungal infections in patients with rheumatoid arthritis: an explorative analysis from the German RABBIT register
Objectives: To explore characteristics and treatment of patients with rheumatoid arthritis (RA) with invasive fungal infections (IFIs) and to describe infection details and outcome. Methods: IFIs reported to the German RABBIT (Rheumatoid Arthritis: Observation of Biologic Therapy) register between May 2001 and December 2023 were analysed using a two-stage approach. First, a detailed case description, including a comparison of cases by infection outcome, was conducted using routine register data and hospital discharge letters. Second, a multivariable time-dependent Cox regression model was fitted to analyse associations with IFI development using routine register data only. Results: Among 22 535 patients with RA, 69 IFIs occurred (incidence rate: 0.65/1000 patient-years), with a case fatality of 35% (n=24). Causative pathogens were Pneumocystis jirovecii (35%), Candida spp (33%) and Aspergillus spp (13%). Patients with IFIs were on average 65.4 years old; 54% were female, 80% ever-smokers, 84% glucocorticoid (GC) users and 91% had any infection-risk associated comorbidity at hospitalisation. IFI development was associated with older age (HR 1.36 per 10 years (95% CI 1.05 to 1.76)), male sex (HR 1.92 (95% CI 1.14 to 3.21)), ever-smoking (HR 2.43 (95% CI 1.35 to 4.37)), cardiovascular disease (HR 3.03 (95% CI 1.80 to 5.10)), chronic lung disease (HR 2.09 (95% CI 1.21 to 3.61)), other autoimmune disease (HR 2.11 (95% CI 1.10 to 4.07)), and the use of GCs (HR 1.17 (95% CI 1.11 to 1.22)). Conclusion: In patients with RA, IFIs are rare but life-threatening. They occur particularly in patients who are predisposed to infection due to relevant comorbidities, a history of smoking or both. Except for GC use, the overall impact of targeted RA treatment on the risk of IFI appears to be less relevant than that of multimorbidity.
- Top Cited PapersOpen Access
- 25 June 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (11) , 1779-1790
Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register
- 25 June 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (11) , 1779-1790
Top Cited PapersOpen AccessComparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register